/

Società

Da

Non verificato

Daiichi Sankyo

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

107 comunicati stampa

Guarda tutti i comunicati

14/09/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Eventi

Industria

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Fonte

Emittente

1.00

0

01/09/2026

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Fonte

Emittente

1.00

0

28/08/2026

Eventi

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Cardiologia

Biotecnologia

Nuovi dati di Daiichi Sankyo evidenziano l'effetto dell'acido bempedoico nella gestione della dislipidemia e del rischio cardiovascolare nella pratica clinica

Fonte

Emittente

1.00

0

28/08/2026

Eventi

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Cardiologia

Biotecnologia

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk

Fonte

Emittente

1.00

0

27/08/2026

Oncologia

Salute

Medicina - Varie

Sanità

Farmaceutica

Biotecnologia

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

Fonte

Emittente

1.00

0

26/08/2026

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer

Fonte

Emittente

1.00

0

24/08/2026

Mercato del lavoro

Attrezzature medico-sanitarie

Salute

Sanità

Farmaceutica

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

Fonte

Emittente

1.00

0

24/08/2026

Mercato del lavoro

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio

Fonte

Emittente

1.00

0

17/08/2026

Industria

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Fonte

Emittente

1.00

0

31/07/2026

Web e Social Network

Telefonia e Varie

Mercato azionario

Scienza

Medicina - Varie

Sanità

Biotecnologia

Farmaceutica

Salute

Oncologia

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0